TECLens

The Future of Vision Correction

health AI/medtech diagnostics and devices for ophthalmology

Visit website LinkedIn ↗

StageSeries A

Founded2013

Employees11

LocationStamford, CT

Business modelB2B2C / device with potential service model (in-office treatment)

About

TECLens is a clinical-stage ophthalmic medical device company, pioneering non-invasive personalized corneal cross-linking technology (qCXL™) for vision correction. Our innovative CXLens® system uses patterned ultraviolet (UV) light to gently reshape the cornea with continuous biomechanical control. qCXL is designed to be a comfortable, safe, and effective alternative to traditional refractive surgeries. TECLens’ breakthrough technology aims to set a new standard in precision, accessibility, and patient experience—redefining vision correction with innovation that improves quality of life. Caution – Investigational device. Limited by Federal (or United States) law to investigational use.

Product

Value proposition: A non-invasive, in-office vision correction technology using qCXL™ and the CXLens® device to strengthen and reshape the cornea for refractive errors and presbyopia, with future expansion to other eye conditions.
Target customers: ophthalmology clinics, eye care providers, hospitals offering refractive and corneal treatments

Founders

David E. Acker — Co-Founder
Patrick Lopath — Co-Founder & COO

Products

qCXL™ technologyCXLens® device

Key features

quantitative corneal cross-linking (qCXL)real-time ultrasound monitoringtargeted UV light guidancepersonalized precision planningnon-invasive in-office procedurepotential future applications for additional refractive conditions

Technologies

qCXL™CXLens® devicereal-time ultrasoundUV light-based corneal reshapingpersonalized planning

Target conditions

myopiapresbyopiakeratoconushyperopiamyopia progression in childrenlow-order myopia in adults

Care settings

in-office clinical settingophthalmology cliniceye care practice

Partnerships

potential collaborations with ophthalmology practices

Investors

Johnson & Johnson Innovation – JJDC Inc.Yonjin CapitalRimonci CapitalSunmed Capital

News

First Patient Treated in TECLens First-in-Human Clinical Study of Revolutionary Non-Invasive Vision Correction Technology · 2026-02-24T13:00:00.000Z
TECLens Secures $9.3 Million Series A Funding to Advance Its Non-Invasive Refractive Technology · 2025-02-11T00:00:00.000Z
TECLens: Funding, Team & Investors | Startup Intros · 2026-04-16T00:00:00.000Z
First Patient Treated in TECLens First-in-Human Clinical Study of Revolutionary Non-Invasive Vision Correction Technology - BioSpace · 2026-02-25T03:42:43.000Z
Study Underway for TECLens' Non-Invasive Vision Correction Technology | Medical Product Outsourcing · 2026-04-20T00:00:00.000Z
TECLens conducts first clinical trial for non-surgical vision correction technology | HealthCare Middle East & Africa - No.1 Health & Pharma Manufacturing Industry Publication · 2026-03-05T08:14:09.000Z

Browse similar startups

Related startups

BlissGene Therapeutics Incorporated — Watertown, CT
CHS Business Solutions LLC — Fairfield, CT
CureBytes, Inc. — Norwalk, CT
Texas Cancer Institute — Austin, TX
Texas Cancer Specialists — Fort Worth, TX
The Broadway Elder Living and Rehabilitation — Lockport, LA
THE CENTER FOR DERMATOLOGY AND SKIN CARE, INC — South Charleston, WV
THE CENTER FOR REPRODUCTIVE MEDICINE, P.C. — Mobile, AL
THE DERMATOLOGY AND SKIN CANCER CLINIC OF ALASKA — Soldotna, AK
THE DERMATOLOGY AND SKIN CARE CENTER OF BIRMINGHAM, P.C. — Birmingham, AL
The DR K Podcast — New York, NY
The Heart Center, Huntsville AL — huntsville, AL

Profile updated Jul 29, 2026. Sources: teclens.com, linkedin.com